TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

• Published in: Future oncology (London, England) England), 2024, Vol.20 (37), p.2927-2936
• Main Authors: Okamoto, Isamu, Kuyama, Shoichi, Girard, Nicolas, Lu, Shun, Franke, Fábio, Li, Ziming, Danchaivijitr, Pongwut, Han, Ji-Youn, Sun, Jong-Mu, Sugawara, Shunichi, Pan, Edward, Ren, Natalie, Chen, Aiying, Rajagopalan, Rachana, Lisberg, Aaron E
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Clinical Trial Protocol; Clinical Trials, Phase III as Topic; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Method; Middle Aged; Pemetrexed - administration & dosage; Pemetrexed - therapeutic use; Progression-Free Survival; Randomized Controlled Trials as Topic
• ISSN: 1479-6694; 1744-8301; 1744-8301
• DOI: 10.1080/14796694.2024.2409621

For patients with advanced/metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations and low (